MDS | Tumor

CURE’s myelodysplastic syndrome (MDS) page is an extensive resource of cancer information featuring the latest myelodysplastic syndrome news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on MDS.

Cyclophosphamide ‘Opens the Registry Up’ for Stem Cell Transplants

July 31st 2024, 7:00pm

Article

Post-transplant cyclophosphamide decreased the risk of complications in patients with blood cancers who underwent a stem cell transplant from an unrelated donor.

My Invisible Losses That Emerge from Cancer

July 10th 2024, 5:00pm

Article

Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.

Some With MDS May Benefit from Delaying Stem Cell Transplants

July 1st 2024, 3:00pm

Article

For patients with MDS who benefit from delaying transplants, it’s important to take care of their health while savoring their time before transplant.

Don Omar Announces Being Cancer Free, ‘General Hospital’ Star Opens Up About Cancer and More

June 21st 2024, 3:27pm

Article

From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.

My Feeling of Survivor’s Guilt

June 19th 2024, 5:00pm

Article

As a cancer survivor, I realize that life doesn’t always go the way we think it will, but it doesn’t erase the guilt.

FDA-Approved Rytelo a ‘Game Changer’ for Some Patients with MDS

June 17th 2024, 1:00pm

Article

Approximately half of the patients with MDS who responded to treatment with Rytelo went a year without needing a blood transfusion, one expert explained.

FDA Approves Rytelo for Some With Low- to Intermediate-1-risk MDS

June 7th 2024, 1:23pm

Article

The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.

Reblozyl Continues to Improve MDS Transfusion Independence

June 3rd 2024, 7:00pm

Article

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.

Safety Profile of Lower-Dose Oral Onureg Remains Consistent in Lower-Risk MDS

June 3rd 2024, 1:00pm

Article

The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.

Cancer Remission Is Wonderful But Scary

May 27th 2024, 5:00pm

Article

I’ve experienced mixed emotions during my periods of remission for my myelodysplastic syndrome.